Curium to merge with Lantheus in $8B deal

Curium US Holdings agreed to acquire Lantheus for $102.50 per share in cash at closing plus up to $12.00 per share in contingent value rights, for a total transaction value of up to $8.0 billion.

“Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries.”indovizka.com

• 1 source
• indovizka.comCurium Announces Definitive Agreement to Merge with LantheusRedaksiJan 21, 2018

Summarized from public sources; check the original articles before acting on it.